Worth Watching: Is Major Move Coming For Regeneron Pharmaceuticals Inc After This Gap Down?

Worth Watching: Is Major Move Coming For Regeneron Pharmaceuticals Inc After This Gap Down?

The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) gapped down by $9.83 today and has $372.20 target or 8.00% below today’s $404.56 share price. The 7 months technical chart setup indicates high risk for the $40.32 billion company. The gap down was reported on Nov, 18 by Barchart.com. If the $372.20 price target is reached, the company will be worth $3.23B less.
Gaps down are helpful for identifying a resistance level and to could also be used as a tradeable event. If traders are short the stock and it experiece gap down, then its usually advisable to hold the short for a bigger down move. Back-tests of such patterns show that two-thirds of the these patterns the stock performance worsens after the gap. The area gaps close 91% of the time, the breakaway gaps 1%, the continuation gaps 9% and the exhaustion gaps 64%. The stock decreased 3.69% or $15.52 during the last trading session, hitting $404.56. About 1.49 million shares traded hands or 65.34% up from the average. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 3.28% since April 15, 2016 and is uptrending. It has underperformed by 1.34% the S&P500.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Ratings Coverage

Out of 19 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 9 rate it a “Buy”, 1 “Sell”, while 9 “Hold”. This means 47% are positive. Regeneron Pharmaceuticals Inc. has been the topic of 41 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Buy” rating by Citigroup on Thursday, February 25. The stock has “Outperform” rating given by Leerink Swann on Monday, August 3. Brean Capital reinitiated the stock with “Buy” rating in Tuesday, March 8 report. The firm has “Outperform” rating given on Friday, February 5 by Leerink Swann. TH Capital maintained the stock with “Neutral” rating in Monday, August 10 report. The firm has “Market Perform” rating by Wells Fargo given on Wednesday, April 20. RBC Capital Markets maintained Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rating on Monday, July 27. RBC Capital Markets has “Outperform” rating and $570 price target. The company was maintained on Thursday, August 6 by Argus Research. As per Tuesday, February 16, the company rating was upgraded by Chardan Capital Markets. On Tuesday, August 4 the stock rating was maintained by Chardan Capital Markets with “Buy”.

According to Zacks Investment Research, “Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron’s platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)”

Insitutional Activity: The institutional sentiment increased to 1.19 in Q2 2016. Its up 0.44, from 0.75 in 2016Q1. The ratio is positive, as 51 funds sold all Regeneron Pharmaceuticals Inc shares owned while 154 reduced positions. 50 funds bought stakes while 193 increased positions. They now own 70.88 million shares or 9.49% less from 78.30 million shares in 2016Q1.
Moreover, Ithaka Grp Incorporated Limited Liability Company has 3.21% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 63,393 shares. Ftb Advisors Inc has 0% invested in the company for 36 shares. Hsbc Holding Plc accumulated 46,304 shares or 0.04% of the stock. Bessemer Grp Incorporated holds 409 shares or 0% of its portfolio. Commonwealth Bankshares Of Australia holds 0% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 268 shares. Princeton Alpha Management L P accumulated 1,897 shares or 0.12% of the stock. Blackrock Grp holds 0.11% or 598,453 shares in its portfolio. Ballentine Ptnrs Ltd Co holds 638 shares or 0.02% of its portfolio. Gabelli Funds Ltd Company holds 0.01% or 6,000 shares in its portfolio. Polar Cap Limited Liability Partnership holds 0.09% or 13,909 shares in its portfolio. Ncm Capital Advisers Inc last reported 1.32% of its portfolio in the stock. Glg Ltd Liability Co last reported 4,542 shares in the company. Finemark Retail Bank last reported 0% of its portfolio in the stock. Invesco owns 824,283 shares or 0.11% of their US portfolio. M&T National Bank holds 56,865 shares or 0.13% of its portfolio.

Insider Transactions: Since May 24, 2016, the stock had 1 insider buy, and 4 insider sales for $20.44 million net activity. RYAN ARTHUR F also sold $396,640 worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Tuesday, May 24. 2,125 Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares with value of $956,250 were sold by GOLDSTEIN JOSEPH L. Sanofi bought 64,731 shares worth $23.55 million.

More recent Regeneron Pharmaceuticals Inc (NASDAQ:REGN) news were published by: Fool.com which released: “Regeneron Pharmaceuticals, Inc. Dropped 14.3% in October — Here’s Why” on November 08, 2016. Also Forbes.com published the news titled: “Regeneron Pharmaceuticals Becomes Oversold (REGN)” on October 31, 2016. Prnewswire.com‘s news article titled: “Science Magazine Once Again Names Regeneron the Best Company to Work For” with publication date: October 27, 2016 was also an interesting one.

REGN Company Profile

Regeneron Pharmaceuticals, Inc., incorporated on January 11, 1988, is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. The Firm commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. The Company’s marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. The Firm has over 10 product candidates in clinical development. These consist of Trap clinical programs and over 10 human monoclonal antibody product candidates. The Firm has generated each of the antibodies using its VelocImmune technology. The Company’s ARCALYST (rilonacept) Injection for subcutaneous Use is available in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children over 12 year.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment